Haematological and Bone Marrow Cancers
Haematological cancers are cancers which affect the blood, bone marrow and lymph nodes. The most common types include leukaemias, lymphomas, myelomas and myeloproliferative disorders (MPDs). All affect cell types that are important for regulating the activity of the immune system.
Leukaemias start in blood-forming tissue such as the bone marrow and results in the release of large numbers of abnormal blood cells into the bloodstream. Leukaemias may be classed as acute or chronic and may stem from lymphocytic or myeloid cells. This equates to four subtypes; acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).
Lymphomas impact on lymphocytes and presents as a solid tumour that generally develops in the lymph nodes, spleen, bone marrow or blood. There are two subtypes, Hodgkin lymphoma and non-Hodgkin’s lymphoma. Myelomas lead to an accumulation of plasma cells in bone marrow which impacts on the production of normal blood cells.
Related news and insights
AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL).
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk chronic lymphocytic leukaemia (CLL) compared to ibrutinib .
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for Imbruvica (ibrutinib), extending the approved indication in chronic lymphocytic leukaemia (CLL) to include combination with rituximab for previously untreated adult patients.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.